Press release promises timelines without required disclaimers
The Phase II press release claims regulatory approval and commercial launch are on track, but doesn't include the standard risk factors and assumptions that are required for that kind of forward-looking statement.
InfoDisclosure Integrity
Evidence
“The Company expects regulatory approval and commercial launch on its previously disclosed timeline.”
Triggering filings
| Filed | Type | Title |
|---|---|---|
| Feb 04, 2025 | News Release | Cascade BioSciences Reports Positive CSB-204 Phase II Interim Data |
| Mar 28, 2025 | MD&A | Management's Discussion & Analysis — Year ended December 31, 2024 |
Metadata
- Issuer
- Cascade BioSciences Inc.
- Score
- 44
- Status
- Open
- Raised
- Feb 05, 2025 · 527d
flag-csbx-fls